PPI Deprescribing and the Evidence on Long-Term Harms

The one principle that reorganizes the whole debate

The American Gastroenterological Association's 2022 clinical practice update on de-prescribing proton pump inhibitors rests on a single, clarifying rule: a PPI should be stopped or reduced when there is no longer a valid reason to take it, not because a study linked it to a frightening outcome. Most of the widely publicized long-term harms come from observational research that can detect an association but cannot prove the drug caused it. An observed harm, on its own, is not a reason to withdraw a medicine that someone genuinely needs. That distinction, between the reason to be on a drug and the fear of being on it, is what the update asks clinicians and patients to hold onto.

What the update actually says

Written by Targownik, Fisher, and Saini and published in Gastroenterology (2022;162:1334-1342), the update offers ten best practice advice statements for the ambulatory setting. The guiding premise is unremarkable and sound: no one should take any medication without a reasonable expectation of benefit. From there it is practical. Every patient on a PPI should have the indication reviewed and documented. Anyone without a definitive indication should be considered for a de-prescribing trial. Most people on twice-daily dosing can step down to once-daily.

The statement that does the real work is the one about what does not justify stopping. A history or presence of a so-called PPI-associated adverse event, or the mere presence of risk factors for one, is explicitly listed as an inappropriate reason to independently discontinue the drug. The trigger for deprescribing is the absence of an indication, full stop.

Association is not causation

Long-term PPI use has been linked in the literature to pneumonia, Clostridioides difficile infection, hip fracture, chronic kidney disease, dementia, low magnesium, vitamin B12 deficiency, and gastric cancer. Nearly all of those signals come from observational cohorts, and observational data carry predictable traps. Confounding by indication means the people who stay on PPIs for years tend to be older, sicker, and on more medications than those who never start. Healthy-adherer bias, protopathic bias (treating the early symptom of a disease that has not yet been diagnosed), and residual confounding can each manufacture an association that is not a cause.

The cleanest way to separate the two is a randomized trial, and one exists. In a randomized comparison within the COMPASS trial, 17,598 patients with vascular disease were assigned to pantoprazole or placebo and followed for a median of about three years (Moayyedi and colleagues, Gastroenterology 2019). Across the full list of feared outcomes, pantoprazole showed no convincing increase in risk, with the possible exception of enteric infections. When you randomize, the scary associations largely dissolve. That is what you would expect if confounding, rather than the drug, was driving much of the observational signal.

Why an observed harm is not itself a reason to stop

The logic becomes concrete once you weigh both sides. Suppose a drug plausibly, even if slightly, raises the risk of some outcome, while it clearly prevents gastrointestinal bleeding in a person taking aspirin and an anticoagulant. Stopping it to chase away a small and unproven harm can trade a real benefit for a hypothetical one, and produce net harm. The update reflects this asymmetry directly. It names groups who should generally not be deprescribed: people with complicated reflux disease (severe erosive esophagitis, esophageal ulcer, or peptic stricture), Barrett's esophagus, eosinophilic esophagitis, or idiopathic pulmonary fibrosis, and anyone at high risk of upper gastrointestinal bleeding. For them the indication is the answer, and the adverse-event headlines are noise.

The rebound trap

Stopping a long-term PPI has a predictable pharmacologic consequence that is easy to misread. Suppressing acid raises the hormone gastrin, and when the drug is removed the stomach briefly oversecretes acid. In a double-blind trial, healthy volunteers who had no reflux to begin with developed heartburn, acid regurgitation, or dyspepsia after PPI withdrawal at a rate around 44 percent, roughly three times the 15 percent seen in the placebo group (Reimer and colleagues, Gastroenterology 2009). A patient who feels that surge naturally concludes the drug was necessary all along. It usually was not. The update advises warning people in advance that transient symptoms are expected, and it accepts either a taper or abrupt cessation. Bridging with a lower-potency agent such as an H2 blocker or antacid can smooth the few weeks it takes for acid output to normalize.

What a sensible step-down looks like

The sequence the update supports is straightforward. Confirm whether a genuine indication still exists. If dosing is twice daily, drop to once daily. If no indication remains, trial the patient off the drug or onto on-demand use. Set expectations about rebound, offer a lower-potency bridge if needed, and reassess after a few weeks rather than at the first uncomfortable day. The goal is fewer pills where they add nothing, not zero pills as a slogan.

The takeaway for readers

This article is educational and is not medical advice. The practical message is narrow and important: do not stop a PPI on your own because of a frightening headline, and do not assume the drug is harmless either. Ask a different question than the internet tends to ask. Not "could this drug hurt me" but "is there still a reason for me to be taking it." If the answer is yes, the reported associations rarely change the calculus. If the answer is no, that, and not fear, is the reason to step down, ideally with the clinician who prescribed it.